Literature DB >> 3243228

Isoelectric focusing of alpha-1 acid glycoprotein (orosomucoid) in immobilized pH-gradients with 8M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system.

C B Eap1, P Baumann.   

Abstract

A method allowing a clear separation of the different variants of desialylated alpha 1-acid glycoprotein (orosomucoid) has been developed using isoelectric focusing in immobilized pH gradients, supplemented with 8 M urea and 2% v/v 2-mercaptoethanol. Immunoblotting with two antibody-steps afforded high sensitivity and permitted the detection of about 700 pg of alpha 1-acid glycoprotein in a 20 microL plasma sample diluted 1:28 672. A one year old bloodstrain, kept at room temperature, could easily be phenotyped.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3243228     DOI： 10.1002/elps.1150091005

Source DB:  PubMed          Journal:  Electrophoresis        ISSN： 0173-0835            Impact factor:   3.535


  11 in total

1.  Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice.

Authors:  W van Dijk; O Pos; M E van der Stelt; H J Moshage; S H Yap; L Dente; P Baumann; C B Eap
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

2.  Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.

Authors:  A Barrail-Tran; F Mentré; C Cosson; C Piketty; C Chazallon; L Gérard; P M Girard; A M Taburet
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 3.  Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function.

Authors:  W van Dijk; E C Havenaar; E C Brinkman-van der Linden
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

Review 4.  Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.

Authors:  F Hervé; S Urien; E Albengres; J C Duché; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

5.  Biantennary glycans as well as genetic variants of alpha1-acid glycoprotein control the enantioselectivity and binding affinity of oxybutynin.

Authors:  Tomoko Kimura; Akimasa Shibukawa; Katsumi Matsuzaki
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

6.  Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants.

Authors:  L Tomei; C B Eap; P Baumann; L Dente
Journal:  Hum Genet       Date:  1989-12       Impact factor: 4.132

7.  Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein.

Authors:  F Herve; E Gomas; J C Duche; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

8.  Orosomucoid (alpha-1 acid glycoprotein) phenotyping by use of immobilized pH gradients with 8 M urea and immunoblotting. A new variant encountered in a population study.

Authors:  C B Eap; C Cuendet; P Baumann
Journal:  Hum Genet       Date:  1988-10       Impact factor: 4.132

9.  Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants.

Authors:  T Nakagawa; S Kishino; S Itoh; M Sugawara; K Miyazaki
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

10.  Drug-binding energetics of human α-1-acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations.

Authors:  Johnny X Huang; Matthew A Cooper; Mark A Baker; Mohammad A K Azad; Roger L Nation; Jian Li; Tony Velkov
Journal:  J Mol Recognit       Date:  2012-12       Impact factor: 2.137
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.